论文部分内容阅读
IgA肾炎是世界范围内最常见的肾小球肾炎。这种类型的肾炎患者占需要接受透析的肾病患者总数的10%。大约40%的IgA肾炎患者在确诊后20年内会发展成为终末期肾脏病,这种情况将危及患者生命。目前还没有任何治疗IgA肾炎的疗法获得FDA的批准。近日,Omeros公司宣布治疗肾小球肾炎的在研新药OMS721在临床2期试验结束后跟踪研究产生的新数据。
IgA nephritis is the most common glomerulonephritis in the world. This type of nephritis accounts for 10% of the total number of patients who require dialysis. Approximately 40% of patients with IgA nephritis develop end-stage renal disease within 20 years of diagnosis, which can be life-threatening. There are currently no FDA approved treatments for IgA nephritis. Recently, Omeros Inc. announced that the new drug OMS721 for the treatment of glomerulonephritis will follow up the new data generated after the Phase 2 clinical trial.